Table 1.

Anticancer treatments that act via BH3-only proteins

Treatment	Likely mode of action	Tumor or cell type	BH3-only protein(s) implicated	References
Glucocorti-coid	Activation of transcription	ALL	Bim and Puma	Bouillet et al. (1999), Villunger et al. (2003)
Imatinib	Tyrosine kinase inhibitor	CML	Bim and Bad	Kuribara et al. (2004), Kuroda et al. (2006)
Paclitaxel	Microtubule stabilizer	Lymphocytes, epithelial cancers	Bim	Bouillet et al. (1999), Tan et al. (2005)
Genotoxic damage (via wt p53)	p53-induced transcription	Multiple cell types	Puma and/or Noxa	Jeffers et al. (2003), Villunger et al. (2003)
Bortezomib	Proteasome inhibitor	Various cancers	Bim and/or Bik	Nikrad et al. (2005), Tan et al. (2005)
Bortezomib		Melanoma, myeloma	Noxa	Fernandez et al. (2005), Qin et al. (2005)
Bortezomib		Squamous cell carcinoma	Noxa	Fribley et al. (2006)
Epoxomicin	Proteasome inhibitor	Tumor with wt p53	Puma	Concannon et al. (2006)

Abbreviations: ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia.